Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that ...

ADARx Pharmaceuticals has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing ...

Novartis’ Ionis-partnered drug designed to lower levels of Lp (a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular events ...

Pfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier ...

Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million ...

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates ...

Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly ...

Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to ...

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to ...

The month of September 2025 marked a low point for relations between the U.K. government and Big Pharma.  | September 2025 ...